Dulaglutide Reduced Kidney Hyperfiltration and Protein Leakage in Teens with Type 2 Diabetes | Research

The takeaway

In a post hoc analysis of 154 youth with type 2 diabetes, dulaglutide reduced glomerular hyperfiltration and proteinuria over 26 weeks — early kidney damage markers that worsened in the placebo group.

Hyperfiltration & proteinuria both decreased
Both early kidney damage markers improved with dulaglutide but worsened with placebo in youth with type 2 diabetes (p=0.014 and p=0.004)

What the researchers found

Over 26 weeks, dulaglutide reduced eGFR by 5.8 mL/min/1.73 m² versus only 0.1 in the placebo group (p=0.016). This decrease was concentrated in participants who started with glomerular hyperfiltration — a paradoxically high filtration rate that signals early kidney damage.

Critically, the prevalence of both glomerular hyperfiltration and proteinuria (protein in the urine) decreased with dulaglutide but increased with placebo (p=0.014 and p=0.004, respectively). In the context of diabetic kidney disease, a reduction in hyperfiltration is considered protective — it means the kidneys are working under less stress, potentially slowing progression to irreversible damage.

Why it matters

Type 2 diabetes in youth is a growing epidemic, and these young patients develop kidney disease faster and more severely than adults with the same condition. Glomerular hyperfiltration is one of the earliest detectable signs of kidney damage, often appearing before any symptoms. Finding that a GLP-1 agonist can normalize this early pathology in teenagers could mean the difference between kidney health and kidney failure decades later — if the protective effect proves durable.

How the study worked

This was a post hoc analysis of kidney laboratory data from the AWARD-PEDS study, a completed placebo-controlled trial of dulaglutide for blood sugar control in 154 youth (ages 10-18) with type 2 diabetes. Researchers examined changes in eGFR, glomerular hyperfiltration prevalence, proteinuria, and albuminuria from baseline to 26 weeks.

What this study cannot tell us

This was a post hoc analysis, meaning kidney outcomes were not the original primary endpoint, and the study wasn't powered to detect kidney differences. The sample size of 154 is small for kidney outcome conclusions. The 26-week duration is too short to determine whether the kidney benefits translate to long-term prevention of diabetic kidney disease. The eGFR decrease could reflect hemodynamic effects rather than structural kidney protection. The impact on hard kidney endpoints remains unclear.

How to read the evidence

This is a post hoc analysis of a randomized controlled trial. While the underlying AWARD-PEDS trial was well-designed, the kidney outcomes were not pre-specified, and the analysis is exploratory. The small sample size and short duration limit the strength of conclusions.

When this study was published

Published in 2024 in Diabetes Care, a leading journal. This represents some of the most recent data on GLP-1 agonist kidney effects in pediatric type 2 diabetes — a population with very limited evidence.

The bigger picture

This study adds to mounting evidence that GLP-1 agonists protect the kidneys beyond just lowering blood sugar. In adults, the FLOW trial demonstrated semaglutide's kidney benefits. But this is rare data in youth — pediatric kidney outcomes from GLP-1 drugs are almost nonexistent because most large trials exclude children. The finding that dulaglutide addresses hyperfiltration, one of the earliest and most treatable stages of diabetic nephropathy, is particularly relevant for young patients who have decades of diabetes ahead of them.

Questions still open

Do the kidney-protective effects of dulaglutide in youth persist beyond 26 weeks and translate to reduced diabetic kidney disease risk over years?
Would semaglutide or tirzepatide show even stronger kidney benefits in the pediatric type 2 diabetes population?

Common questions

What is glomerular hyperfiltration and why is it bad?

Glomerular hyperfiltration means the kidneys are filtering blood at an abnormally high rate. While this might sound efficient, it actually represents kidney stress — imagine an engine running too fast. Over time, this overwork damages the kidney's filtering units (glomeruli), leading to scarring, protein leakage into urine, and eventually kidney failure. Catching and reversing hyperfiltration early is one of the best ways to prevent diabetic kidney disease.

Why is kidney protection especially important in teenagers with type 2 diabetes?

Youth-onset type 2 diabetes is more aggressive than the adult form — kidney disease develops faster and leads to kidney failure at younger ages. These patients have decades of diabetes ahead of them, so even small protective effects early on can compound into major benefits over a lifetime. Finding drugs that protect teenage kidneys could prevent the need for dialysis or transplant in middle age.

Read the original research

Dulaglutide and Glomerular Hyperfiltration, Proteinuria, and Albuminuria in Youth With Type 2 Diabetes: Post Hoc Analysis of the AWARD-PEDS Study.

Diabetes care, 47(9), 1617-1621

View on PubMed ↗Publisher’s paper ↗

Citation

Bjornstad, Petter; Arslanian, Silva A; Hannon, Tamara S; Zeitler, Philip S; Francis, Jennie L; Curtis, Alexandra M; Turfanda, Ibrahim; Cox, David A. (2024). Dulaglutide and Glomerular Hyperfiltration, Proteinuria, and Albuminuria in Youth With Type 2 Diabetes: Post Hoc Analysis of the AWARD-PEDS Study.. Diabetes care, 47(9), 1617-1621. https://doi.org/10.2337/dc24-0322